Alexandra B. Kornbluh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alexandra B. Kornbluh has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Ilana Kahn
Department of Pediatrics, Children's National Hospital, George Washington University Medical School, Washington, District of Columbia
4 shared publications- Elizabeth Pickup
Children's National Hospital
3 shared publications Leigh Sepeta
Center for Neuroscience Research, Children’s National Hospital, Washington, USA
3 shared publicationsWilliam Suslovic
Department of Laboratory Medicine, Children’s National Hospital, Washington, USA
3 shared publications- Andrew Christiana
New York University Comprehensive Epilepsy Center, 223 E34th St, New York, NY 10016, USA
2 shared publications - Catherine Otten
Department of Pediatrics, Seattle Children's/University of Washington, Seattle, Washington
2 shared publications
Latest Publications
- 22 October 2026
- Published by SAGE Publications in Journal of Child Neurology
Outpatient Infusion Therapy for Pediatric Status Migrainosus: Real-World Clinical Outcomes From a Tertiary Care Center
Pediatric patients with status migrainosus frequently present to the emergency department for acute treatment, despite growing evidence that outpatient infusion centers are associated with pain reduction and high patient satisfaction in adults. In this single-center study, 19 patients with status migrainosus were prospectively enrolled prior to outpatient infusion with intravenous normal saline, ketorolac, and antiemetic (prochlorperazine or metoclopramide), followed by valproic acid if pain score did not reach 0/10. Patients completed pre- and post-infusion surveys. All patients had reduced pain intensity scores after infusion, with an average pain reduction of 4.3 points on a 0- to 10-point scale ( P < .001). Infusion was associated with a significant decrease in photophobia ( P = .008) and phonophobia ( P = .02). Although compliance with follow-up survey was low, 100% (6/6) of respondents reported they would consider outpatient infusion for future episodes of status migrainosus. These findings suggest that outpatient infusion for pediatric status migrainosus is a feasible alternative to the emergency department.
- 22 October 2026
- Published by SAGE Publications in Journal of Child Neurology
Outpatient Infusion Therapy for Pediatric Status Migrainosus: Real-World Clinical Outcomes From a Tertiary Care Center
Pediatric patients with status migrainosus frequently present to the emergency department for acute treatment, despite growing evidence that outpatient infusion centers are associated with pain reduction and high patient satisfaction in adults. In this single-center study, 19 patients with status migrainosus were prospectively enrolled prior to outpatient infusion with intravenous normal saline, ketorolac, and antiemetic (prochlorperazine or metoclopramide), followed by valproic acid if pain score did not reach 0/10. Patients completed pre- and post-infusion surveys. All patients had reduced pain intensity scores after infusion, with an average pain reduction of 4.3 points on a 0- to 10-point scale ( P < .001). Infusion was associated with a significant decrease in photophobia ( P = .008) and phonophobia ( P = .02). Although compliance with follow-up survey was low, 100% (6/6) of respondents reported they would consider outpatient infusion for future episodes of status migrainosus. These findings suggest that outpatient infusion for pediatric status migrainosus is a feasible alternative to the emergency department.
- 9 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 85-91
Onabotulinumtoxin A is an effective preventative treatment of chronic and daily pediatric migraine
- 9 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 85-91
Onabotulinumtoxin A is an effective preventative treatment of chronic and daily pediatric migraine
- Open Access
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
Peripheral Nerve Blocks in the Treatment of Pediatric Headaches
Background: Peripheral nerve blocks (PNBs), while an effective treatment of headache disorders in adults, have been infrequently studied in pediatric patients. This study aimed to assess practice patterns in PNB use in pediatric headache.Methods: This was a prospective study conducted between 2020 and 2022 in a headache clinic at a tertiary children’s hospital. Pre- and post-injection survey data were prospectively obtained from 16 patients over 32 visits where PNBs, including greater and lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blocks, were administered.Results: Participants ranged in age from 10 to 19 years old, with a median age of 16.7 years, and the majority were diagnosed with migraine without aura. Among the total cohort, mean pain scores, obtained on a 10-point scale, decreased from 4.4 pre-injection to 2.8 post-injection (p=0.003). When stratified by specific headache diagnosis, only patients with migraine without aura reported significant pain decrease (p=0.007).Conclusion: These preliminary findings support that PNBs may be a promising treatment in pediatric headache, particularly in migraine without aura.
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPeripheral Nerve Blocks in the Treatment of Pediatric Headaches
Background: Peripheral nerve blocks (PNBs), while an effective treatment of headache disorders in adults, have been infrequently studied in pediatric patients. This study aimed to assess practice patterns in PNB use in pediatric headache.Methods: This was a prospective study conducted between 2020 and 2022 in a headache clinic at a tertiary children’s hospital. Pre- and post-injection survey data were prospectively obtained from 16 patients over 32 visits where PNBs, including greater and lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blocks, were administered.Results: Participants ranged in age from 10 to 19 years old, with a median age of 16.7 years, and the majority were diagnosed with migraine without aura. Among the total cohort, mean pain scores, obtained on a 10-point scale, decreased from 4.4 pre-injection to 2.8 post-injection (p=0.003). When stratified by specific headache diagnosis, only patients with migraine without aura reported significant pain decrease (p=0.007).Conclusion: These preliminary findings support that PNBs may be a promising treatment in pediatric headache, particularly in migraine without aura.
- Open Access
- 10 December 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Characterizing CSF inflammatory proteomics in pediatric post-hemorrhagic hydrocephalus and Anti-NMDAR encephalitis
Neuroinflammation is a key contributor to pathology in many central nervous system (CNS) diseases. While cerebrospinal fluid (CSF) proteomic studies in adu
- 10 December 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessCharacterizing CSF inflammatory proteomics in pediatric post-hemorrhagic hydrocephalus and Anti-NMDAR encephalitis
Neuroinflammation is a key contributor to pathology in many central nervous system (CNS) diseases. While cerebrospinal fluid (CSF) proteomic studies in adu
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (5) , e200192
Practical Approach to Longitudinal Neurologic Care of Adults With X-Linked Adrenoleukodystrophy and Adrenomyeloneuropathy
Although X-linked adrenoleukodystrophy (ALD) has historically been considered a childhood disease managed by pediatric neurologists, it is one of the most common leukodystrophies diagnosed in adulthood. An increase in both male and female adults reaching diagnosis due to familial cases identified by state newborn screening panels and more widespread use of genetic testing results in a large cohort of presymptomatic or early symptomatic adults. This population is in urgent need of standardized assessments and follow-up care. Adults with ALD/adrenomyeloneuropathy (AMN) may be diagnosed in a variety of ways, including after another family member is identified via genetic testing or newborn screening, presenting for symptomatic evaluation, or following diagnosis with primary adrenal insufficiency. Significant provider, patient, and systems-based barriers prevent adult patients with ALD/AMN from receiving appropriate care, including lack of awareness of the importance of longitudinal neurologic management. Confirmation of and education about the diagnosis should be coordinated in conjunction with a genetic counselor. Routine surveillance for adrenal insufficiency and onset of cerebral ALD (CALD) in men should be performed systematically to avoid preventable morbidity and mortality. While women with ALD do not usually develop cerebral demyelination or adrenal insufficiency, they remain at risk for myeloneuropathy and are no longer considered “carriers.” After diagnosis, patients should be connected to the robust support networks, foundations, and research organizations available for ALD/AMN. Core principles of neurologic symptom management parallel those for patients with other etiologies of progressive spastic paraplegia. Appropriate patient candidates for hematopoietic stem cell transplant (HSCT) and other investigational disease-modifying strategies require early identification to achieve optimal outcomes. All patients with ALD/AMN, regardless of sex, age, or symptom severity, benefit from a multidisciplinary approach to longitudinal care spearheaded by the neurologist. This review proposes key strategies for diagnostic confirmation, laboratory and imaging surveillance, approach to symptom management, and guidance for identification of appropriate candidates for HSCT and investigational treatments.
- 1 October 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (5) , e200192
Open AccessPractical Approach to Longitudinal Neurologic Care of Adults With X-Linked Adrenoleukodystrophy and Adrenomyeloneuropathy
Although X-linked adrenoleukodystrophy (ALD) has historically been considered a childhood disease managed by pediatric neurologists, it is one of the most common leukodystrophies diagnosed in adulthood. An increase in both male and female adults reaching diagnosis due to familial cases identified by state newborn screening panels and more widespread use of genetic testing results in a large cohort of presymptomatic or early symptomatic adults. This population is in urgent need of standardized assessments and follow-up care. Adults with ALD/adrenomyeloneuropathy (AMN) may be diagnosed in a variety of ways, including after another family member is identified via genetic testing or newborn screening, presenting for symptomatic evaluation, or following diagnosis with primary adrenal insufficiency. Significant provider, patient, and systems-based barriers prevent adult patients with ALD/AMN from receiving appropriate care, including lack of awareness of the importance of longitudinal neurologic management. Confirmation of and education about the diagnosis should be coordinated in conjunction with a genetic counselor. Routine surveillance for adrenal insufficiency and onset of cerebral ALD (CALD) in men should be performed systematically to avoid preventable morbidity and mortality. While women with ALD do not usually develop cerebral demyelination or adrenal insufficiency, they remain at risk for myeloneuropathy and are no longer considered “carriers.” After diagnosis, patients should be connected to the robust support networks, foundations, and research organizations available for ALD/AMN. Core principles of neurologic symptom management parallel those for patients with other etiologies of progressive spastic paraplegia. Appropriate patient candidates for hematopoietic stem cell transplant (HSCT) and other investigational disease-modifying strategies require early identification to achieve optimal outcomes. All patients with ALD/AMN, regardless of sex, age, or symptom severity, benefit from a multidisciplinary approach to longitudinal care spearheaded by the neurologist. This review proposes key strategies for diagnostic confirmation, laboratory and imaging surveillance, approach to symptom management, and guidance for identification of appropriate candidates for HSCT and investigational treatments.
- 17 July 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 159, 12-15
Isolated Psychiatric Symptoms in Children With Anti-N-Methyl-d Aspartate Receptor Encephalitis
- 17 July 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 159, 12-15
Isolated Psychiatric Symptoms in Children With Anti-N-Methyl-d Aspartate Receptor Encephalitis
- 9 March 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 85, 105526
Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease
- 9 March 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 85, 105526
Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease
- 29 November 2023
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 30 (4-5) , 594-599
Longitudinal evaluation of serum MOG-IgG titers in MOGAD after initiation of maintenance immunoglobulin: A case series
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system. Immunoglobulin (Ig) has been used as a maintenance therapy to prevent relapses in MOGAD, but the impact of Ig on serum MOG-IgG titers is unclear. Objective: To characterize the variation in serum MOG-IgG titers after initiation of Ig treatment in people with MOGAD. Methods: We conducted a retrospective study of 10 patients with a diagnosis of MOGAD and available serum MOG-IgG titers before and after initiation of maintenance Ig treatment. Results: We found that most of the patients remained MOG-IgG seropositive while on Ig treatment with a reduced or unchanged titer, despite a lack of disease activity. Conclusions: This case series suggests that the mechanism of action of Ig therapy in MOGAD is not exclusively dependent on MOG-IgG titer reduction.
- 29 November 2023
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 30 (4-5) , 594-599
Longitudinal evaluation of serum MOG-IgG titers in MOGAD after initiation of maintenance immunoglobulin: A case series
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system. Immunoglobulin (Ig) has been used as a maintenance therapy to prevent relapses in MOGAD, but the impact of Ig on serum MOG-IgG titers is unclear. Objective: To characterize the variation in serum MOG-IgG titers after initiation of Ig treatment in people with MOGAD. Methods: We conducted a retrospective study of 10 patients with a diagnosis of MOGAD and available serum MOG-IgG titers before and after initiation of maintenance Ig treatment. Results: We found that most of the patients remained MOG-IgG seropositive while on Ig treatment with a reduced or unchanged titer, despite a lack of disease activity. Conclusions: This case series suggests that the mechanism of action of Ig therapy in MOGAD is not exclusively dependent on MOG-IgG titer reduction.
- Open Access
- 1 July 2023
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 10 (4)
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis
Objectives How brain MRI lesions associate with outcomes in pediatric anti-NMDA receptor encephalitis (pNMDARE) is unknown. In this study, we correlate T2-hyperintense MRI brain lesions with clinical outcomes in pNMDARE. Methods This was a multicenter retrospective cohort study from 11 institutions. Children younger than 18 years with pNMDARE were included. One-year outcomes were assessed by the modified Rankin Score (mRS) with good (mRS ≤2) and poor (mRS ≥3) outcomes. Results A total of 175 pNMDARE subjects were included, with 1-year mRS available in 142/175 (81%) and 60/175 (34%) had abnormal brain MRIs. The most common T2-hyperintense lesion locations were frontal, temporal, and parietal. MRI features that predicted poor 1-year outcomes included abnormal MRI, particularly T2 lesions in the frontal and occipital lobes. After adjusting for treatment within 4 weeks of onset, improvement within 4 weeks, and intensive care unit admission, MRI features were no longer associated with poor outcomes, but after multiple imputation for missing data, T2 frontal and occipital lesions associated with poor outcomes. Discussion Abnormal frontal and occipital lesions on MRI may associate with 1-year mRS in pNMDARE. MRI of the brain may be a helpful prognostication tool that should be examined in future studies.
- 1 July 2023
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 10 (4)
Open AccessMRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis
Objectives How brain MRI lesions associate with outcomes in pediatric anti-NMDA receptor encephalitis (pNMDARE) is unknown. In this study, we correlate T2-hyperintense MRI brain lesions with clinical outcomes in pNMDARE. Methods This was a multicenter retrospective cohort study from 11 institutions. Children younger than 18 years with pNMDARE were included. One-year outcomes were assessed by the modified Rankin Score (mRS) with good (mRS ≤2) and poor (mRS ≥3) outcomes. Results A total of 175 pNMDARE subjects were included, with 1-year mRS available in 142/175 (81%) and 60/175 (34%) had abnormal brain MRIs. The most common T2-hyperintense lesion locations were frontal, temporal, and parietal. MRI features that predicted poor 1-year outcomes included abnormal MRI, particularly T2 lesions in the frontal and occipital lobes. After adjusting for treatment within 4 weeks of onset, improvement within 4 weeks, and intensive care unit admission, MRI features were no longer associated with poor outcomes, but after multiple imputation for missing data, T2 frontal and occipital lesions associated with poor outcomes. Discussion Abnormal frontal and occipital lesions on MRI may associate with 1-year mRS in pNMDARE. MRI of the brain may be a helpful prognostication tool that should be examined in future studies.
- Open Access
- 8 October 2022
- Published by Elsevier in Neuroimmunology Reports
- Vol. 2
Anti-N-methyl-D-aspartic acid receptor encephalitis after recurrent herpes simplex infection: A case report and literature review
- 8 October 2022
- Published by Elsevier in Neuroimmunology Reports
- Vol. 2
Open AccessAnti-N-methyl-D-aspartic acid receptor encephalitis after recurrent herpes simplex infection: A case report and literature review